Transgenic A53T Mice Have Astrocytic α-Synuclein Aggregates in Dopamine and Striatal Regions

The accumulation of α-synuclein in astrocytes in Parkinson's disease is considered to be secondary to neuronal accumulation. The aim of this study to identify whether astrocytes accumulate small α-synuclein aggregates before or after neurons in the nigrostriatal pathway.

Fixed serial midbrain and striatal sections from M83 A53T transgenic mouse model of Parkinson's disease and wild-type controls were histologically processed for multiplex labelling of α-synuclein and astrocytic markers and astrocyte quantitation performed on digital images using QuPath software.

The density of astrocytes within the substantia nigra pars compacta was approximately 30% greater compared with other sampled regions (p < 0.005). Small aggregates of α-synuclein were observed in astrocytic processes, including in wild-type mice where a quarter of all astrocytes had an obvious α-synuclein aggregate. Compared to wild-type, A53T transgenic astrocytes had significantly enlarged somas (p < 0.001) with more processes (p < 0.001) consistent with a reactive phenotype. The A53T transgenic mice had more than double the numbers of astrocytes (p < 0.001) and 2.5 times more astrocytes with α-synuclein aggregates compared to wild-type mice (p < 0.001).

These data suggest that small α-synuclein aggregates are normally cleared by astrocytes and that the substantia nigra pars compacta requires more astrocytic support for this function than other midbrain dopaminergic regions or the striatum. This adds another vulnerability factor to those already known for the substantia nigra with early deficits in clearance of small α-synuclein aggregates by astrocytes associated with increased astrocytic reactivity in the A53T transgenic mouse model.